Malaysia's drug regulator has given conditional approval for Chinese biopharmaceutical company Sinovac Biotech's (Nasdaq:SVA) COVID-19 vaccine to be used in young people aged between 12 and 17, Reuters news agency reported on Friday.

The health ministry stated that the drugs regulator had advised priority for Sinovac's vaccine among teenagers without co-morbidities or allergy problems, or otherwise deemed unsuitable for the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) vaccine.

Reportedly, teenagers younger than 18 in Malaysia started receiving COVID-19 doses last month, after vaccinations of more than 80% of adults were completed.